This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Archey, W. B. Articles by Arrick, B. A. Search for Related Content PubMed PubMed Citation Articles by Archey, W. B. Articles by Arrick, B. A.

Methylation of CpGs as a Determinant of Transcriptional Activation at Alternative Promoters for Transforming Growth Factor-ß3¹

Departments of Physiology [W. B. A.] and Medicine [M. P. S., G. C. A., B. A. A.], Dartmouth Medical School, Hanover, New Hampshire 03755

The human transforming growth factor-ß3 (TGF-ß3) gene has a typical CpG island, the core of which is centered just upstream of its principle promoter. Activation of an alternative downstream promoter, leading to the production of a truncated mRNA lacking the portion of the 5' noncoding region responsible for translational inhibition of TGF-ß3 mRNA, is only evident in breast cancer cells. We compared the methylation status of genomic DNA isolated from a panel of breast (SKBR-3 and T47-D) and non-breast cancer (HT-1080, A673, and A375) cell lines by sequencing sodium metabisulfite-treated DNA. In all cell lines, the core of the TGF-ß3 CpG island was predominantly unmethylated, irrespective of promoter usage associated with that cell line. In contrast, we observed a marked difference in methylation at 19 CpG sites immediately flanking and downstream of the alternative promoter’s transcription initiation site. Specifically, the non-breast cancer cell lines exhibited nearly complete methylation of these CpG sites, whereas in the breast cancer cell lines, these CpGs were predominantly unmethylated. Our data support the hypothesis that methylation of a limited number of CpGs at the periphery of an otherwise unmethylated CpG island underlies the transcriptional repression of the downstream promoter in non-breast cancer cells, thereby serving to regulate the use of alternative promoters for TGF-ß3.

This article has been cited by other articles:

				J. Torrisani, N. Hanoun, H. Laurell, F. Lopez, J.-J. Maoret, A. Souque, C. Susini, P. Cordelier, and L. Buscail Identification of an Upstream Promoter of the Human Somatostatin Receptor, hSSTR2, Which Is Controlled by Epigenetic Modifications Endocrinology, June 1, 2008; 149(6): 3137 - 3147. [Abstract] [Full Text] [PDF]

				N. J. Laping, J. I. Everitt, K. S. Frazier, M. Burgert, M. J. Portis, C. Cadacio, L. I. Gold, and C. L. Walker Tumor-Specific Efficacy of Transforming Growth Factor-{beta}RI Inhibition in Eker Rats Clin. Cancer Res., May 15, 2007; 13(10): 3087 - 3099. [Abstract] [Full Text] [PDF]

				A. Ventura, L. Luzi, S. Pacini, C. T. Baldari, and P. G. Pelicci The p66Shc Longevity Gene Is Silenced through Epigenetic Modifications of an Alternative Promoter J. Biol. Chem., June 14, 2002; 277(25): 22370 - 22376. [Abstract] [Full Text] [PDF]

				S. Matsukura, K. Miyazaki, H. Yakushiji, A. Ogawa, K. Harimaya, Y. Nakabeppu, and M. Sekiguchi Expression and Prognostic Significance ofO6-Methylguanine-DNA Methyltransferase in Hepatocellular, Gastric, and Breast Cancers Ann. Surg. Oncol., December 1, 2001; 8(10): 807 - 816. [Abstract] [Full Text] [PDF]